← Back to Search

Other

LY3841136 + Tirzepatide for Obesity with Type 2 Diabetes

Phase 2
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
W8M-MC-LAA2: Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliters per minute (mL/min)/1.73 m2
W8M-MC-LAA2: Have a history of acute or chronic pancreatitis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial aims to study the safety and effectiveness of a drug called LY3841136 for managing weight in individuals with Type 2 Diabetes. The study will also look at how combining LY3841136

Who is the study for?
This trial is for adults with obesity or overweight who also have Type 2 Diabetes. Participants will be involved in the study for about 64 weeks to test weight management treatments.
What is being tested?
The study tests LY3841136 and Tirzepatide, alone or combined, for managing weight. Some participants may receive a placebo instead to compare effects.
What are the potential side effects?
Possible side effects of LY3841136 and Tirzepatide could include gastrointestinal issues like nausea or diarrhea, potential low blood sugar levels, fatigue, and injection site reactions.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidney function is reduced, with an eGFR below 45 mL/min.
Select...
I have a history of pancreatitis.
Select...
I have a history of slow heartbeats.
Select...
I have had symptoms of gallbladder problems in the last 2 years.
Select...
My high blood pressure is not well-controlled.
Select...
I have type 1 diabetes or a history of severe diabetes complications.
Select...
I have liver disease symptoms not caused by nonalcoholic fatty liver disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

10Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: LY3841136 Dose 3 + Tirzepatide Dose 3Experimental Treatment2 Interventions
Participants will receive LY3841136 SC and Tirzepatide SC
Group II: LY3841136 Dose 3Experimental Treatment1 Intervention
Participants will receive LY3841136 SC
Group III: LY3841136 Dose 2 + Tirzepatide Dose 3Experimental Treatment2 Interventions
Participants will receive LY3841136 SC and Tirzepatide SC
Group IV: LY3841136 Dose 2 + Tirzepatide Dose 2Experimental Treatment2 Interventions
Participants will receive LY3841136 SC and Tirzepatide SC
Group V: LY3841136 Dose 2 + Tirzepatide Dose 1Experimental Treatment2 Interventions
Participants will receive LY3841136 SC and Tirzepatide SC
Group VI: LY3841136 Dose 2Experimental Treatment1 Intervention
Participants will receive LY3841136 SC
Group VII: LY3841136 Dose 1 + Tirzepatide Dose 1Experimental Treatment2 Interventions
Participants will receive LY3841136 SC and Tirzepatide SC
Group VIII: LY3841136 Dose 1Experimental Treatment1 Intervention
Participants will receive LY3841136 subcutaneously (SC)
Group IX: Tirzepatide Dose 3Active Control1 Intervention
Participants will receive Tirzepatide SC
Group X: PlaceboPlacebo Group1 Intervention
Participants will receive placebo administered SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3841136
2022
Completed Phase 1
~150
Tirzepatide
2019
Completed Phase 3
~7520

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,675 Previous Clinical Trials
3,463,633 Total Patients Enrolled
70 Trials studying Obesity
55,297 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,388 Previous Clinical Trials
427,028 Total Patients Enrolled
52 Trials studying Obesity
34,839 Patients Enrolled for Obesity
~233 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top